Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection

Liver International

Volumn 34, Issue 6, 2014, Pages 953-960

  Li, Tao ^a   Qin, Lun Xiu ^b   Zhou, Jian ^b   Sun, Hui Chuan ^b   Qiu, Shuang Jian ^b   Ye, Qing Hai ^b   Wang, Lu ^b   Tang, Zhao You ^b   Fan, Jia ^b  

^a SHANDONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Adjuvant therapy; Intrahepatic cholangiocarcinoma; Prognosis; Recurrence; Risk factors

Indexed keywords

10 HYDROXYCAMPTOTHECIN; EPIRUBICIN; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GAMMA-GLUTAMYLTRANSFERASE, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGED; BILE DUCT NEOPLASMS; BLOOD; CHI SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; DISEASE FREE SURVIVAL; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; SURGERY; TIME; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902536280     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12364     Document Type: Article

References (40)

1. Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 2011; 117: 2170-7.
2. Wakabayashi H, Hashimoto N, Okano K, et al. Clinicopathological comparison between intrahepatic cholangiocarcinoma arising in livers positive and negative for hepatitis B or C virus. Liver Int 2008; 28: 717-8.
3. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-8.
4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7.
5. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16: 14-22.
6. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual, 7th edn. New York, NY: Springer, 2009.
7. Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16: 3048-56.
8. Ikai I, Arii S, Okazaki M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-91.
9. Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008; 113: 1614-22.
10. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013; 153: 811-8.
11. Kim JH, Yoon HK, Sung KB, et al. Adjuvant chemotherapy following curative intent hepatectomy for intrahepatic cholangiocarcinoma: results from a multi-institutional analysis of 575 patients. J Clin Oncol 2012; 30 (suppl; abstr 4110).
12. Shinohara ET, Mitra N, Guo M, et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008; 72: 1495-501.
13. Li T, Ji Y, Zhi XT, et al. A comparison of hepatic mucinous cystic neoplasms with biliary intraductal papillary neoplasms. Clin Gastroenterol Hepatol 2009; 7: 586-93.
14. Sirica AE, Dumur CI, Campbell DJ, et al. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol 2009; 7: S68-78.
15. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006; 26: 1047-53.
16. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-21.
17. Tao LY, He XD, Qu Q, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int 2010; 30: 215-21.
18. Kokudo N, Arita J. Staging for intrahepatic cholangiocarcinoma. Liver Int 2010; 30: 931-3.
19. Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinoma-a population-based study. Ann Surg Oncol 2008; 15: 600-8.
20. Schlinkert RT, Nagorney DM, Van Heerden JA, et al. Intrahepatic cholangiocarcinoma: clinical aspects, pathology and treatment. HPB Surg 1992; 5: 95-101; discussion 101-2.
21. Farges O, Fuks D. Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol Clin Biol 2010; 34: 191-9.
22. Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143: 366-74.
23. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-9.
24. Zhou L, Liu C, Meng FD, et al. Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev 2012; 13: 483-6.
25. Li T, Qin LX, Gong X, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer 2013; 119: 126-35.
26. Fentiman IS. Gamma-glutamyl transferase: risk and prognosis of cancer. Br J Cancer 2012; 106: 1467-8.
27. Lim JS, Yang JH, Chun BY, et al. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress. Free Radic Biol Med 2004; 37: 1018-23.
28. Aishima S, Fujita N, Mano Y, et al. p62 + Hyaline inclusions in intrahepatic cholangiocarcinoma associated with viral hepatitis or alcoholic liver disease. Am J Clin Pathol 2010; 134: 457-65.
29. Grossi S, Sumberaz A, Gosmar M, et al. DNA damage in peripheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses. Eur J Gastroenterol Hepatol 2008; 20: 22-5.
30. Hanigan MH, Frierson HF Jr, Swanson PE, et al. Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol 1999; 30: 300-5.
31. Dawson J, Smith GD, Boak J, et al. Gamma-Glutamyltransferase in human and mouse breast tumours. Clin Chim Acta 1979; 96: 37-42.
32. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29: 3140-5.
33. Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92: 2374-83.
34. Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193: 384-91.
35. Song BC, Chung YH, Kim JA, et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 2001; 91: 2386-93.
36. Liou TC, Shih SC, Kao CR, et al. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol 1995; 23: 563-8.
37. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-21.
38. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008; 99: 2037-44.
39. Gupta S, Kobayashi S, Phongkitkarun S, et al. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 2006; 41: 516-21.
40. Liu L, Ren ZG, Shen Y, et al. Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: relevance of epithelial-mesenchymal transition. Cancer Sci 2010; 101: 120-8.